Associate Professor of Clinical Pharmacy
University of California San Diego
La Jolla, CA, United States
Dr. Jacinda Abdul-Mutakabbir (JAM) is an Associate Professor of Clinical Pharmacy and Researcher at the University of California San Diego in the Skaggs School of Pharmacy and Pharmaceutical Sciences and the Division of the Black Diaspora and African American Studies. Her research focuses on antimicrobial resistance and stewardship, where she identifies health disparities in various infectious diseases to inform targeted interventions for vulnerable communities. She has published over 70 articles, including several focused on identifying racial and social vulnerability differences in various infectious disease states, including Clostridium difficile infection, candidemia, and others. She was recognized as a top scientist under 30 for her early contributions to antimicrobial resistance research by the European Society of Clinical Microbiology and Infectious Diseases in 2020 and was invited to discuss her research at 25th the Presidential Advisory Council on Combatting Antimicrobial Resistant Bacteria Public Meeting. Additionally, the United States Public Health Services has recognized her dedication to improving public health, as she was the 2017 recipient of the USPHS Outstanding Service Award, and she currently serves as an appointed member of the CVSH Health Equity National Advisory Board. In 2021, she received the Society of Infectious Disease Pharmacists (SIDP) Gita Patel Best Practice Award and the Wayne State University Warrior of Distinction Alumni Award. In 2023, Dr. Abdul-Mutakabbir was named the recipient of the Infectious Diseases Society of America (IDSA) Clinical Practice Innovation Award, and in 2024, she received the American College of Clinical Pharmacy (ACCP) New Clinical Practitioner Award. Most recently, she was appointed editor for Clinical Microbiology Reviews, an American Society of Microbiology (ASM) Journal. Dr. Abdul-Mutakabbir remains an active member of several professional organizations, including the American College of Clinical Pharmacy (ACCP), the American Society for Microbiology (ASM), the Infectious Diseases Society of America (IDSA), and the Society for Healthcare Epidemiology of America (SHEA).
Disclosure(s): No financial relationships to disclose.
Monday, October 20, 2025
9:30 AM - 9:55 AM US ET
												
											
163 - Lowering Barriers to Diagnostics Access to Reduce Health Inequities and Improve Outcomes
Tuesday, October 21, 2025
1:45 PM - 3:00 PM US ET
												
											
412 - Impact of Limited Access to Diagnostics on the Detection of AMR in Vulnerable Communities
Tuesday, October 21, 2025
1:45 PM - 2:10 PM US ET